Provided herein are methods of mitigating (such as eliminating) interference in a serological assay caused by a therapeutic anti-CD47 antibody. Also provided are anti-idiotypic antibodies for use in such methods. Also provided are methods of transfusing donor blood to a subject who is under treatment with a therapeutic anti-CD47 antibody.

The present invention relates to antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.

The invention provides improved methods for detecting anti-BCMA CAR expression on T cells.

Provision of an affinity carrier using a mutant VHH antibody. An affinity carrier comprising: a solid phase carrier; and an immunoglobulin-binding protein bound to the solid phase carrier; wherein the immunoglobulin-binding protein comprises a mutant VHH antibody or a fragment of the mutant VHH antibody that recognizes an epitope in at least one region selected from the group consisting of amino acids 127 to 184 of SEQ ID NO: 22 and amino acids 13 to 210 of SEQ ID NO: 23.

The present disclosure relates generally to antibodies and binding fragments thereof that bind to anti-CD123 antibodies, chimeric antigen receptors (CARs), or antibody binding fragments. In particular, the disclosed anti-idiotype antibodies and fragments bind to anti-CD123 antibodies, CARs, or fragments thereof and comprise novel complementary determining regions (CDRs). Finally, the present disclosure relates to methods of using the disclosed antibodies and fragments thereof to expand and/or activate CD123-CAR-expressing immune cells, detecting or quantifying CD123-CARs, and isolating CD123-CAR-expressing immune cells.

Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.

Recombinant cell surface capture proteins and detection molecules that are useful for isolating and detecting cells that produce a secreted heterodimeric protein of interest (POI) that has an immunoglobulin CH3 domain and/or substituted CH3 domain are provided. Recombinant cell surface capture proteins and detection molecules that isolate and detect bispecific antibodies are also provided. The invention also provides recombinant antigen-binding proteins that are capable of recognizing and binding to proteins of interest that contain a CH3 domain and/or a modified CH3 domain, such as a CH3 domain with or without amino acid substitutions at H95 and Y96 (IMGT).

The present invention relates to antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.

Isolated antigen binding molecules that specifically bind to a BCMA binding molecule are provided. The antigen binding molecules may be used in the methods provided herein. Specifically, monoclonal anti-idiotypic antibodies are provided which bind to the antigen-binding portion of a BCMA-binding molecule, in particular of anti-BCMA CARs.